cbdMD (YCBD) Short term Debt (2016 - 2024)
cbdMD (YCBD) reported Short term Debt of $362021.0 for Q4 2024, down 69.09% sequentially from $1.2 million in Q3 2024.
cbdMD (YCBD) Short term Debt (2016 - 2024) Analysis & Trends
cbdMD (YCBD) has 4 years of Short term Debt data on file, last reported at $362021.0 in Q4 2024.
- For the quarter ending Q4 2024, Short term Debt changed N/A year-over-year to $362021.0; the trailing twelve-month figure through Dec 2024 stood at $362021.0 (changed N/A YoY), and the FY2024 full-year result was $1.2 million, changed N/A from the prior year.
- Short term Debt fell to $362021.0 in Q4 2024, from $1.2 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $1.2 million in Q3 2024 to a low of $362021.0 in Q4 2024.
- A 3-year average of $870911.6 and a median of $939826.0 in 2020 frame the typical range for Short term Debt.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | cbdMD | 438,678.80 | -2.95 Mn | 3.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 362,021.00 |
| Sep 30, 2024 | 1.17 Mn |
| Mar 31, 2021 | 1.03 Mn |
| Dec 31, 2020 | 939,826.00 |
| Sep 30, 2020 | 854,000.00 |
| Sep 30, 2016 | 797,547.00 |